Cancer Treatment Centers of America (CTCA) in Philadelphia, PA, is the first US center to investigate the use of nanotherapy for the treatment of metastatic lung cancer. The center is launching the first clinical trial using advanced nanotherapy developed by Nanospectra Biosciences, Inc, in Irvine, CA. The trial will allow oncologists to use AuroLase Therapy—a new approach to the treatment of solid tumors using laser energy to heat nanoparticles, which are absorbed by the tumor but not by healthy tissue.
“The use of heat to destroy malignant tumors is not new to cancer care, but this technology holds the promise of offering new and exciting treatment options for tumor destruction with minimal collateral damage to adjacent tissue and structures,” said Mark Lund, MD, Director of Interventional Pulmonology, Bronchoscopy and Intensive Care Unit, and the Advanced Center for Lung and Thoracic Oncology at CTCA. Nanospectra Biosciences press release, November 14, 2012
